BioLineRx Ltd. (BLRX)
- Previous Close
0.6316 - Open
0.6289 - Bid 0.6100 x 200
- Ask 0.6501 x 200
- Day's Range
0.6200 - 0.6499 - 52 Week Range
0.5100 - 2.3000 - Volume
101,135 - Avg. Volume
288,308 - Market Cap (intraday)
51.156M - Beta (5Y Monthly) 0.82
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4500 - Earnings Date Nov 4, 2024 - Nov 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.83
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
www.biolinerx.comRecent News: BLRX
View MorePerformance Overview: BLRX
Trailing total returns as of 9/16/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BLRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BLRX
View MoreValuation Measures
Market Cap
52.95M
Enterprise Value
44.14M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.69
Price/Book (mrq)
3.66
Enterprise Value/Revenue
2.59
Enterprise Value/EBITDA
-0.67
Financial Highlights
Profitability and Income Statement
Profit Margin
-176.67%
Return on Assets (ttm)
-35.23%
Return on Equity (ttm)
-171.94%
Revenue (ttm)
17.05M
Net Income Avi to Common (ttm)
-30.12M
Diluted EPS (ttm)
-0.4500
Balance Sheet and Cash Flow
Total Cash (mrq)
40.06M
Total Debt/Equity (mrq)
223.55%
Levered Free Cash Flow (ttm)
-15.81M